ERBC works hand in hand with academic and industrial partners during the early stages of drug development to demonstrate the preclinical proof-of-concept of the test compound, ultimately aiming to convert it into a drug candidate.

ERBC performs a range in vivo assays and offers numerous animal models of human diseases covering almost all therapeutic areas.

At ERBC, we consider this initial step of in vivo proof-of-concept studies as essential to minimize risks of late attrition during clinical trials reminding that the lack of efficacy in the clinic is one of first cause of late attrition during drug development. ERBC offers the clear advantage to run these pivotal studies under GLP (Good Laboratory Practice).